Globenewswire·2026-03-16 23:25Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. for the period between March 26, 2025, and November 4, 2025, due to alleged misleading statements regarding the safety and commercial viability of its product DCCR [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Soleno Therapeutics made false and misleading statements about the safety of DCCR, particularly concerning significant safety concerns related to excess fluid retention in clinical trial participants [5]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, affecting its commercial viability and leading to potential adverse events post-launch [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and securing over $438 million for investors in 2019 [4]. Group 3: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].